MX2022013195A - Uso de proteina surfactante d para tratar infecciones virales. - Google Patents

Uso de proteina surfactante d para tratar infecciones virales.

Info

Publication number
MX2022013195A
MX2022013195A MX2022013195A MX2022013195A MX2022013195A MX 2022013195 A MX2022013195 A MX 2022013195A MX 2022013195 A MX2022013195 A MX 2022013195A MX 2022013195 A MX2022013195 A MX 2022013195A MX 2022013195 A MX2022013195 A MX 2022013195A
Authority
MX
Mexico
Prior art keywords
surfactant protein
viral infections
treat viral
viral infection
treat
Prior art date
Application number
MX2022013195A
Other languages
English (en)
Inventor
Shawn Grant
Paul Kingma
Raquel Arroyo-Rodríguez
Marc Salzberg
Original Assignee
Airway Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Airway Therapeutics Inc filed Critical Airway Therapeutics Inc
Publication of MX2022013195A publication Critical patent/MX2022013195A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Algunas modalidades de los métodos y composiciones proporcionadas en la presente se refieren al uso de proteína surfactante D (SP-D) para tratar o mejorar una infección viral en un sujeto. En algunas modalidades, la infección viral comprende un coronavirus, como el coronavirus de síndrome respiratorio agudo grave 2 (SARS-CoV-2). Algunas modalidades incluyen el uso de ciertas formulaciones que comprenden una SP-D humana recombinante (rhSP-D).
MX2022013195A 2020-04-22 2021-04-20 Uso de proteina surfactante d para tratar infecciones virales. MX2022013195A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013726P 2020-04-22 2020-04-22
US202063072354P 2020-08-31 2020-08-31
PCT/US2021/028207 WO2021216584A1 (en) 2020-04-22 2021-04-20 Use of surfactant protein d to treat viral infections

Publications (1)

Publication Number Publication Date
MX2022013195A true MX2022013195A (es) 2023-01-05

Family

ID=78270057

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013195A MX2022013195A (es) 2020-04-22 2021-04-20 Uso de proteina surfactante d para tratar infecciones virales.

Country Status (10)

Country Link
US (1) US20230181697A1 (es)
EP (1) EP4138905A4 (es)
JP (1) JP2023523253A (es)
KR (1) KR20230019089A (es)
AU (1) AU2021258178A1 (es)
BR (1) BR112022021423A2 (es)
CA (1) CA3180205A1 (es)
IL (1) IL297362A (es)
MX (1) MX2022013195A (es)
WO (1) WO2021216584A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023145916A1 (ja) * 2022-01-31 2023-08-03 積水メディカル株式会社 肺サーファクタントプロテインを含む液状組成物、及びそれを含む免疫測定キット、並びに肺サーファクタントプロテインの保存安定性向上方法
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933032B2 (en) * 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
US20030221199A1 (en) * 1998-10-20 2003-11-27 Whitsett Jeffrey A. Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
NL2011626C2 (en) * 2013-10-17 2015-04-20 Stichting Tech Wetenschapp Novel polypeptide and uses thereof.
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
KR102205028B1 (ko) * 2020-03-22 2021-01-20 (주)셀트리온 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자
US11123329B1 (en) * 2020-03-23 2021-09-21 Vicore Pharma Ab Use of angiotensin II type 2 receptor agonist
CN112481417B (zh) * 2020-12-24 2022-05-27 山西大学 新冠肺炎病毒分型及突变位点快速检测方法及试剂盒

Also Published As

Publication number Publication date
US20230181697A1 (en) 2023-06-15
CA3180205A1 (en) 2021-10-28
IL297362A (en) 2022-12-01
EP4138905A4 (en) 2024-04-17
EP4138905A1 (en) 2023-03-01
JP2023523253A (ja) 2023-06-02
AU2021258178A1 (en) 2022-11-17
KR20230019089A (ko) 2023-02-07
BR112022021423A2 (pt) 2023-01-03
WO2021216584A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
MX2022010870A (es) Composicion que comprende lactoferrina y cepas bacterianas probioticas para uso oral con accion antiviral.
MX2022013195A (es) Uso de proteina surfactante d para tratar infecciones virales.
JOP20220179A1 (ar) N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها
WO2021191630A8 (en) Coronavirus vaccine
HRP20040059B1 (en) Treatment of nail infections with no
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
WO2005020885A3 (en) Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
TW200509961A (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
BR0112962A (pt) Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet
MX2022016405A (es) Análogos de nucleósido de 1¿-ciano y usos de estos.
NO20091441L (no) Rekonstituerte surfaktanter med forbedrede egenskaper
WO2021236957A3 (en) Ace2 muteins and methods of using the same
DE602005023342D1 (en) S (porcine reproductive und respiratory syndrome) von schweinen
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
MX2022014561A (es) Inhibidores de mek para el tratamiento o prevencion de infecciones por coronavirus y/o tormenta de citocinas por covid-19.
MX2023004933A (es) Proteinas de fusion de ace2 y usos de las mismas.
MX2021011913A (es) Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
MX2010001543A (es) Peptidos de surfactante pulmonar sintetico.
BR9916893A (pt) Tratamento
MX2022016504A (es) Composicion inmunógena contra el coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2).
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
MX2020010030A (es) Metodos y composiciones que comprenden proteina d tensoactiva (sp-d).
WO2023150638A3 (en) Omicron coronavirus vaccine constructs and methods of making and using same